• 1
    Willemze R, Kerl H, Sterry W, Berti E, Cerroni L, Chimenti S, Diaz Perez JL, Geerts ML, Goos M, Knobler R, Ralfkiaer E, Santucci M et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997; 90: 35471.
  • 2
    Edelson RL. Cutaneous T cell lymphoma: the helping hand of dendritic cells. Ann NY Acad Sci 2001; 941: 111.
  • 3
    Dummer R, Häffner A, Hess M, Burg G. A rational approach to the therapy of cutaneous T-cell lymphomas. Onkologie 1996; 19: 22630.
  • 4
    Dippel E, Klemke CD, Goerdt S. Current status of cutaneous T-cell lymphoma: molecular diagnosis, pathogenesis, therapy and future directions. Onkologie 2003; 26: 47783.
  • 5
    Eichmüller S, Usener D, Dummer R, Stein A, Thiel D, Schadendorf D. Serological detection of cutaneous T-cell lymphoma-associated antigens. Proc Natl Acad Sci USA 2001; 98: 62934.
  • 6
    Hartmann TB, Thiel D, Dummer R, Schadendorf D, Eichmüller S. SEREX identification of new tumour-associated antigens in cutaneous T-cell lymphoma. Br J Dermatol 2004; 150: 2528.
  • 7
    Dippel E, Assaf C, Hummel M, Schrag HJ, Stein H, Goerdt S, Orfanos CE. Clonal T-cell receptor γ-chain gene rearrangement by PCR-based GeneScan analysis in advanced cutaneous T-cell lymphoma: a critical evaluation. J Pathol 1999; 188: 14654.
  • 8
    Reddy SA, Okada C, Wong C, Bahler D, Levy R. T cell antigen receptor vaccines for active therapy of T cell malignancies. Ann NY Acad Sci 2001; 941: 97105.
  • 9
    Berger CL, Longley J, Hanlon D, Girardi M, Edelson R. The clonotypic T cell receptor is a source of tumor-associated antigens in cutaneous T cell lymphoma. Ann NY Acad Sci 2001; 941: 10622.
  • 10
    Winter D, Fiebiger E, Meraner P, Auer H, Brna C, Strohal R, Trautinger F, Knobler R, Fischer GF, Stingl G, Maurer D. Definition of TCR epitopes for CTL-mediated attack of cutaneous T cell lymphoma. J Immunol 2003; 171: 271424.
  • 11
    Sandberg Y, Heule F, Lam K, Lugtenburg PJ, Wolvers-Tettero IL, van Dongen JJ, Langerak AW. Molecular immunoglobulin/T-cell receptor clonality analysis in cutaneous lymphoproliferations. Experience with the BIOMED-2 standardized polymerase chain reaction protocol. Haematologica 2003; 88: 65970.
  • 12
    van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL, Delabesse E, Davi F, Schuuring E, Garcia-Sanz R, van Krieken JH, Droese J et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia 2003; 17: 2257317.
  • 13
    Sun Y, Song M, Stevanovic S, Jankowiak C, Paschen A, Rammensee HG, Schadendorf D. Identification of a new HLA-A(*)0201-restricted T-cell epitope from the tyrosinase-related protein 2 (TRP2) melanoma antigen. Int J Cancer 2000; 87: 399404.
  • 14
    Muller-Berghaus J, Olson WC, Moulton RA, Knapp WT, Schadendorf D, Storkus WJ. IL-12 production by human monocyte-derived dendritic cells: looking at the single cell. J Immunother 2005; 28: 30613.
  • 15
    Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, Schmitt E, Knop J, Enk AH. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997; 27: 313542.
  • 16
    Paschen A, Jing W, Drexler I, Klemm M, Song M, Muller-Berghaus J, Nguyen XD, Osen W, Stevanovic S, Sutter G, Schadendorf D. Melanoma patients respond to a new HLA-A*01-presented antigenic ligand derived from a multi-epitope region of melanoma antigen TRP-2. Int J Cancer 2005; 116: 9448.
  • 17
    Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991; 351: 2906.
  • 18
    DiBrino M, Tsuchida T, Turner RV, Parker KC, Coligan JE, Biddison WE. HLA-A1 and HLA-A3 T cell epitopes derived from influenza virus proteins predicted from peptide binding motifs. J Immunol 1993; 151: 59305.
  • 19
    Berger CL, Longley BJ, Imaeda S, Christensen I, Heald P, Edelson RL. Tumor-specific peptides in cutaneous T-cell lymphoma: association with class I major histocompatibility complex and possible derivation from the clonotypic T-cell receptor. Int J Cancer 1998; 76: 30411.
  • 20
    Berger CL, Tigelaar R, Cohen J, Mariwalla K, Trinh J, Wang N, Edelson RL. Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells. Blood 2005; 105: 16407.
  • 21
    Klemke CD, Fritzsching B, Franz B, Kleinmann EV, Oberle N, Poenitz N, Sykora J, Banham AH, Roncador G, Kuhn A, Goerdt S, Krammer PH et al. Paucity of FOXP3(+) cells in skin and peripheral blood distinguishes Sezary syndrome from other cutaneous T-cell lymphomas. Leukemia 2006; 20: 11239.
  • 22
    Orentas RJ, Kohler ME, Johnson BD. Suppression of anti-cancer immunity by regulatory T cells: back to the future. Semin Cancer Biol 2006; 16: 13749.